Fluoxymesterone

"Fluoxymesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.

Descriptor ID

D005474

MeSH Number(s)

D04.808.054.079.429.154.349

D04.808.908.466

Concept/Terms

Below are MeSH descriptors whose meaning is more general than "Fluoxymesterone".

Chemicals and Drugs [D]
Polycyclic Compounds [D04]
Steroids [D04.808]
Androstanes [D04.808.054]
Androstenes [D04.808.054.079]
Androstenols [D04.808.054.079.429]
Androstenediols [D04.808.054.079.429.154]
Fluoxymesterone [D04.808.054.079.429.154.349]
Steroids, Fluorinated [D04.808.908]
Fluoxymesterone [D04.808.908.466]

Below are MeSH descriptors whose meaning is related to "Fluoxymesterone".

Below are MeSH descriptors whose meaning is more specific than "Fluoxymesterone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fluoxymesterone" by people in Harvard Catalyst Profiles by year, and whether "Fluoxymesterone" was a major or minor topic of these publication.

Bar chart showing 6 publications over 5 distinct years, with a maximum of 2 publications in 1998

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1994	1	1
1996	1	1
1997	1	1
1998	2	2
2001	1	1

Below are the most recent publications written about "Fluoxymesterone" by people in Profiles.

Sample size calculations for the two-sample problem using the multiplicative intensity model. Stat Med. 2001 Feb 28; 20(4):557-79.

View in: PubMed
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May; 16(5):1669-76.

View in: PubMed
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181). Am J Clin Oncol. 1998 Feb; 21(1):99-104.

View in: PubMed
The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer. 1997 Mar 15; 79(6):1138-49.

View in: PubMed
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May; 14(5):1589-98.

View in: PubMed
Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1994 Jan; 12(1):45-9.

View in: PubMed
Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study. Ann Oncol. 1992 Nov; 3(9):768-70.

View in: PubMed
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Dec; 9(12):2153-61.

View in: PubMed
pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15; 51(2):624-8.

View in: PubMed
Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):755-60.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

J Pediatr
J Clin Oncol
Cancer Res
Arch Intern Med
Cancer Treat Rep
Cancer
Breast Cancer Res Treat
Blood
Ann Oncol
Am J Clin Oncol